Holen Sie sich die Stockscreener-App
57.85
1.51%
0.86
Vorhandelsmarkt:
57.59
-0.26
-0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.99
Offen:
$57.8
24-Stunden-Volumen:
2.19M
Relative Volume:
1.04
Marktkapitalisierung:
$9.05B
Einnahmen:
$1.22B
Nettoeinkommen (Verlust:
$77.95M
KGV:
118.25
EPS:
0.4892
Netto-Cashflow:
$224.06M
1W Leistung:
-0.03%
1M Leistung:
-15.76%
6M Leistung:
+9.32%
1J Leistung:
-3.78%
1-Tages-Spanne:
$56.92
$58.07
1-Wochen-Bereich:
$54.59
$59.06
52-Wochen-Spanne:
$46.01
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
612-379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
57.85 | 8.92B | 1.22B | 77.95M | 224.06M | 0.4892 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
TECH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TD Asset Management Inc Acquires 36,424 Shares of Bio-Techne Corp $TECH - MarketBeat
Cresset Asset Management Boosts Stake in Bio-Techne - National Today
Cresset Asset Management LLC Increases Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Bio-Techne at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
TECH Technical Analysis & ETF Price Forecast - Intellectia AI
Segall Bryant & Hamill LLC Sells 34,680 Shares of Bio-Techne Corp $TECH - MarketBeat
Champlain Investment Partners LLC Sells 963,441 Shares of Bio-Techne Corp $TECH - MarketBeat
American Century Companies Inc. Boosts Bio-Techne Stake - National Today
American Century Companies Inc. Grows Stock Position in Bio-Techne Corp $TECH - MarketBeat
3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Finviz
Citigroup Trims Stake in Bio-Techne Corp - National Today
Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Royce & Associates Cuts Stake in Bio-Techne Corp - National Today
Bio-Techne Corp (TECH) Stock Analysis: Potential 27.54% Upside Amidst Market Challenges - DirectorsTalk Interviews
Bio-Techne Corp $TECH Shares Sold by Royce & Associates LP - MarketBeat
William Blair Investment Management LLC Grows Holdings in Bio-Techne Corp $TECH - MarketBeat
Citigroup Inc. Sells 97,843 Shares of Bio-Techne Corp $TECH - MarketBeat
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on May 6, 2025. - marketscreener.com
Will Ella CE-IVD Approval in EU Clinical Labs Change Bio-Techne's (TECH) Diagnostic Platform Narrative? - Yahoo Finance
Bio-Techne Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Bio-Techne Corp $TECH Shares Sold by JPMorgan Chase & Co. - MarketBeat
TECH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections - Finviz
Bio-Techne to Present at Upcoming Investor Conferences - Finviz
RSI Alert: Bio-Techne (TECH) Now Oversold - Nasdaq
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know - Yahoo Finance
Bio-Techne Corp $TECH Holdings Trimmed by Granite Investment Partners LLC - MarketBeat
OneDigital Investment Advisors LLC Takes Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (NASDAQ:TECH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Aberdeen Group plc Has $499,000 Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Shares Sold by Vanguard Group Inc. - MarketBeat
Bio-Techne Corp $TECH Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
TECH | Bio-Techne Corp. FinancialsIncome Statement - Quiver Quantitative
17,441 Shares in Bio-Techne Corp $TECH Acquired by Maridea Wealth Management LLC - MarketBeat
Evaluating Bio-Techne (TECH) After Ella’s CE-IVD Milestone And Diagnostics Growth Prospects - Yahoo Finance
Insider plans Rule 144 sale of 1,976 Bio-Techne (TECH) shares - Stock Titan
Bio-Techne (TECH) Gains CE-IVD Certification for Ella Platform i - GuruFocus
Bio-Techne’s Ella platform achieves CE-IVD marking, available for sale in E.U. - TipRanks
Bio-Techne's Ella Immunoassay Platform Receives CE-IVD Marking In EU - Nasdaq
Bio-Techne Corp (TECH): Investor Outlook Highlights 25.56% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories - Investing News Network
Bio-Techne Corp's Ella platform receives CE-IVD marking, available for sale in EU - marketscreener.com
Bio-Techne Corp's Ella Platform Receives CE-Ivd Marking, Available For Sale In EU - TradingView
Fast biomarker test platform gets EU CE-IVD mark for hospital labs - Stock Titan
A | Is Bio Techne Corporation showing insider buyingWeekly Stock Report & Smart Money Movement Tracker - mfd.ru
Why Bio Techne Corporation stock is trending among retail tradersTake Profit & Real-Time Buy Signal Notifications - mfd.ru
ING Groep NV Acquires Shares of 20,266 Bio-Techne Corp $TECH - MarketBeat
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):